Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

No. 651 Dongfeng East Road, Guangzhou, Guangzhou, Guangdong, China
Contact: Study coordinator (Hong Yang Chief Physician) · yanghong@sysucc.org.cn · 86-13560405144

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma · Immunotherapy · Biomarkers

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Borderline Resectable Carcinoma · Unresectable Cancer · Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Shantou, China

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China